Returned for MustBio's KRW 35B Series C for immuno-oncology therapeutics.
Mustbio is an immuno-oncology company dedicated to developing first-in-class and best-in-class multi-specific antibodies for cancer treatment
Mustbio is an immuno-oncology company dedicated to developing first-in-class and best-in-class multi-specific antibodies for cancer treatment. We leverage our innovative platforms, BICSTA™ and STARKINE™, to develop tumor-directed multi-specific antibodies with broader therapeutic potential.